Mirikizumab, a p19-directed antibody against interleukin-23, showed efficacy in the treatment of ulcerative colitis in a phase 2 trial. We conducted two phase 3, randomized, double-blind, ...
We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of ozanimod as induction and maintenance therapy in patients with moderately to severely active ulcerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results